Introduction
T cell large granular lymphocytic leukemia (T-LGL) is a disease caused by clonal expansion of CD3 + CD8 + cytotoxic T lymphocytes (CTL). The vast majority of abnormal cells are terminally differentiated effector CTL, but it is likely that a fraction of corresponding memory cells exists that replenishes the continuous supply of malignant CTL 1 . Under normal physiological conditions, CTL will expand in the course of an immune challenge and then undergo homeostatic apoptosis to prevent untoward reactions directed against the host. According to one hypothesis about the genesis of T-LGL, it is possible that after an initially normal immune response this homeostatic mechanism goes awry, and the T-LGL clone accumulates 2 . The most common complications of T-LGL are lineage-restricted cytopenias, such as neutropenia or pure red cell aplasia. They appear to represent a paraneoplastic syndrome due to the cytokines released and/or direct killing by the T-LGL clone equipped with a specific T cell receptor [3] [4] [5] .
While the pathogenesis of T-LGL remains unknown, lack of homeostatic apoptosis is a remarkable feature of this disease since the clonal CTL abundantly express Fas and FasL 2 , the most effective pathway for T lymphocyte reduction following resolution of an immune response [6] [7] [8] [9] [10] . One potential explanation for this finding is that activation of an opposing survival pathway in T-LGL prevents efficient Fas signaling, thus attenuating apoptotic signals. Given the relatively benign clinical course for most cases of T-LGL, we postulated that its likely cause is aberrant activation of a pro-survival signal transduction pathway, possibly mediated via a cytokine receptor. This mechanism would alter the normal balance between survival and apoptosis pathways and explain why T-LGL lymphoproliferation is not entirely autonomous.
A recent report has revealed that T-LGL exhibit constitutive production of the proinflammatory cytokines RANTES, MIP-1beta and IL-18 3 . Notably, all three cytokines have been shown to induce the phosphoinositide 3-kinase (PI3K) pathway [11] [12] [13] [14] .
PI3K directs one of the most widely studied pro-survival networks, influencing a wide range of cellular functions, including energy metabolism, cell cycle progression, and apoptosis. Furthermore, perturbations in the regulation of the PI3K pathway have been described in various neoplasms (reviewed in 15). In particular, PI3K is integral to the only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From PI3K in T-LGL Schade et. al. 4 malignant process initiated by the Bcr-Abl fusion protein in chronic myelogenous leukemia and also is crucial to survival of chronic B lymphocytic leukemia cells [16] [17] [18] [19] [20] .
We hypothesized that T-LGL exhibit increased PI3K activity, and this may be a key factor in the ability of T-LGL to remain mute to Fas engagement and avoid apoptosis. PI3K pathway activity was analyzed in peripheral blood mononuclear cells (PBMC) and purified CTL from normal donors and T-LGL patients. The relevance of this pathway to T-LGL pathophysiology was interrogated with the use of pharmacologic inhibitors. We propose that aberrant activation of the PI3K pathway in T-LGL is related to the escape from homeostatic apoptosis and presents a novel therapeutic target for this disease.
only. 21 Semenzato et al. 22 and Herling et al. 23 . Clinical description of the patients and their clonal CTL is provided in Table 1 . 
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Membranes were incubated 1 hour at RT in blocking buffer (TBS-T, 5% nonfat milk).
Primary and secondary Abs were diluted 1:1000 in blocking buffer and incubated with the membranes for 1 hr at RT, with washes in TBS-T in between. Detection of HRPconjugated Abs was performed using SuperSignal West Pico (Pierce, Rockford, IL).
Chemiluminescence of all membranes was detected using Hyperfilm ECL (Amersham, Piscataway, NJ). The following rabbit polyclonal antibodies were used: phospho-AKT (S473), phospho-Src family kinase (Y419), phospho-p44/42 ERK (T202/Y204), phospho-GSK-3β (S9), and AKT, were from Cell Signaling Technology (Beverly, MA).
GAPDH was from Trevigen (Gaithersburg, MD). 
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Results
PI3K activity in T-
LGL. Defective signaling along survival pathways may be involved in the pathogenesis of the clonal lymphoproliferation in T-LGL. To assess the potential role of the PI3K pathway in T-LGL, we compared PBMC from T-LGL patients to normal donor PBMC (Fig.1) populations from normal donors we detected very little to no AKT phosphorylation, while the purified clonal T-LGL cells had elevated phospho-AKT (Fig.1A, lanes 3-5) . In each case of T-LGL that we have studied thus far, elevated levels of phoshpo-AKT have been observed.
To further substantiate increased activity of the PI3K pathway in T-LGL, we examined a downstream target of AKT for evidence of phosphorylation. Glycogen synthase kinase-3β (GSK3β) is inactivated by AKT-mediated phosphorylation at serine 9, thus relieving GSK3β inhibition of multiple targets regulating transcription, proliferation, and apoptosis 15, 50 . PBMC from T-LGL patients demonstrate phosphorylated GSK3β (Fig.1B, lanes 1, 3, 5 , and 7), consistent with activation of the PI3K-AKT pathway.
Inhibition of PI3K activity with LY294002 (an inhibitor of PI3K) resulted in reduced to complete loss of AKT dependent GSK3β phosphorylation ( prior to lysis and separation on SDS-PAGE for immunoblotting. While the SFK inhibitor PP2 appeared capable of inhibiting PI3K activity, as shown above, the PI3K inhibitor LY294002 failed to inhibit SFK activity in T-LGL (Fig.2C ). This observation suggests that in T-LGL, a SFK is activated, eventually leading to downstream activation of PI3K.
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The ERK 1/2 MAPK pathway has a high basal level of activation in T-LGL that is PI3K dependent. Constitutive ERK activation has been found in chronic NK lymphoproliferative disease of large granular lymphocytes (NK-LGL), a disorder closely related to T-LGL 27 . The probable cause for ERK activation in NK-LGL was ascribed to constitutively active Ras positioned upstream of ERK.
In the T-LGL, we noted an increase in ERK phosphorylation (Fig. 3) . Since we had shown that PI3K is active in T-LGL, and previously reported that PI3K can regulate ERK activation in T cells 35 , the potential relationship between elevated levels of phosphorylated PI3K and ERK was examined with the use of inhibitors that target the respective pathways. T-LGL were incubated with 50 μM LY294002, or 10 μM U0126
(an inhibitor of MEK, the kinase that phosphorylates and activates ERK) prior to lysis and the lysates were subjected to SDS-PAGE, and immunoblotting. In control T-LGL (not exposed to inhibitors), both AKT and ERK exhibited increased phosphorylation (Fig.3A, lane 1) . Upon addition of the PI3K inhibitor, LY294002, there was nearly complete loss of AKT and ERK phosphorylation, whereas with the ERK inhibitor U0126
there is no discernable loss of phospho-AKT reactivity while phospho-ERK is no longer detectable ( While the PI3K-AKT pathway has been reported to be dependent on ERK 36 , this relationship is likely influenced by the cellular context. In T-LGL, as in other T cells 35 , the hierarchical nature of this association appeared to be completely ERK dependent on PI3K (Fig.3C ). In the two additional T-LGL patients shown here, we further substantiated the above findings that the ERK inhibitor U0126 failed to impede the PI3K pathway (Fig.3C, lanes 3 and 6) . Importantly, the rapid decline in phosphorylated AKT within 15 minutes of LY294002 addition suggests that the increased levels of phospho- 
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AKT noted in T-LGL are not due to a gross defect in the phosphatase activity that normally counteracts PI3K pathway activation (Fig.3C, lanes 2 and 4) , as in the T leukemia cell line Jurkat 37 . Furthermore, in each case of T-LGL that we have studied, elevated levels of PI3K-dependent phosphorylated ERK have been observed.
Importantly, we do not observe phosphorylated ERK in unstimulated T cells from normal donors (Fig.3D ), as we have previously shown 35 . After culturing with IL-2, these T cells are capable of inducing phospho-ERK upon TCR stimulation via OKT3, as shown in the last lane of Fig. 3D .
Inhibition of PI3K in T-
LGL increases the spontaneous rate of apoptosis In view of the fact that PI3K has a central role in regulating cellular metabolism and apoptosis, it is possible that abnormally increased activation of the PI3K pathway is involved in the accumulation T-LGL cells and their relative resistance to apoptosis. For example, T-
LGL express Fas receptor, yet fail to undergo anti-Fas or FasL-mediated apoptosis 2 . We hypothesized that since PI3K was shown to impede Fas signaling 38 , inhibition with LY294002 would lead to increased Fas sensitivity in T-LGL and enhance anti-Fas induced apoptosis (Fig.4) . PBMC from normal donors and T-LGL patients were cultured with 1 μg/ml CH11 (anti-Fas IgM), 50 μM LY294002, or a combination of 1 μg/ml CH11 + 50 μM LY294002 overnight. After 20h, cells were surface stained for CD8 and annexin-V and analyzed via flow cytometry. In PBMC from both normal donors and T-
LGL patients, anti-Fas treatment alone did not result in significant loss of viability or increased annexin-V staining (Fig.4A) . When normal PBMC were treated with 50 μM LY294002 there was no appreciable increase in annexin-V positive CD8 T cells, but a modest increase in annexin-V positive CD8 T cells was observed when LY294002 was combined with anti-Fas (Fig.4A , top and middle rows). T-LGL showed a strikingly contrasting behavior; when PBMC from T-LGL patients were treated with 50 μM LY294002 alone there was a considerable increase in annexin-V positive CD8 T cells, and there was only slight increase in annexin-V staining when LY294002 and anti-Fas were combined (Fig.4A, lower row) . These data suggested that the increased PI3K activity in T-LGL is essential for survival and the mechanism is likely distinct from simply impeding Fas-mediated apoptosis. In addition, when the ERK pathway is only.
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inhibited with U0126, there is only a very mild increase in annexin-V staining (data not shown), suggesting that additional PI3K-mediated pathways are responsible for this prosurvival phenotype in T-LGL.
One T-LGL patient in particular (LGL7) had a large clonal CD8 T cell expansion with 90% of all PBMC comprised of TCR-Vβ2 restricted CD8 T cells. Similar to the above experiments, PBMC from this patient were incubated with 50 μM LY294002 for 20 hours. Upon FACS analysis of Vβ2 T cells, approximately 6% of the cells in the untreated group were annexin-V positive, whereas 30% of the LY294002 treated cells were rendered apoptotic as assessed by the annexin-V staining (Fig.4B) . For experiments involving inhibition of PI3K, we utilized LY294002 at a concentration of 50 μM, previously shown to be optimal for inhibiting the PI3K-AKT pathway, including AKT phosphorylation at S473 [66] [67] [68] [69] [70] . However, to confirm this in our experimental setting, we treated T-LGL cells with increasing concentrations of LY294002 and show increasing annexin-V positive staining by flow cytometry, as indicated in the figure legend (Fig.   4C ).
In addition to the analysis of apoptotic propensity of T-LGL cells using annexin-V flow cytometry, morphologic changes that occur upon treatment with the PI3K inhibitor LY294002 were analyzed on cytospin preparations (Fig.5) . As demonstrated in the control T-LGL PBMC without inhibitors, cultures contained mostly lymphocytes with only occassional macrophages (Fig.5, left panels) . When such cultures were treated with LY294002, there was a dramatic change in the morphology of lymphocytes with increased appearance of apoptotic cells and fragments of cells (Fig.5, right panels) .
Simultaneously, residual macrophages in the LY294002-treated samples appeared unchanged, suggesting a selective susceptibility of T-LGL to PI3K inhibition. When PBMC from normal donors were analyzed under the same conditions, the extensive loss of lymphocyte viability seen with T-LGL was absent (data not shown).
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A key issue regarding T-LGL pathogenesis is the question of what mechanisms
are supporting the ability of the pathologic CTL to avert normal homeostatic apoptosis.
Based on previous reports of constitutive cytokine production by T-LGL, we proposed the mechanism attenuating homeostatic apoptosis may involve signaling through a cytokine receptor and activity of an anti-apoptotic signal transduction pathway. In agreement with such a hypothesis, the proinflammatory cytokines produced in T-LGL are all capable of activating the PI3K pathway, a key mediator of cellular survival (reviewed in 15). In this respect, our results demonstrate that PI3K is active in T-LGL, and inhibition of this pathway sensitizes the CTL to apoptosis. However, it is important to note that LY294002 has recently been shown to inhibit enzymes related to PI3K at similar concentrations, thus we must acknowledge alternative pathways that may be contributing to induction of apoptosis in T-LGL treated with LY294002. Careful consideration of these other enzymes inhibited by LY294002, mentioned below, helps to clarify this issue. mTOR, a downstream target of the PI3K pathway, is not likely playing a major role because treatment of T-LGL cells with rapamycin did not increase annexin-V staining (data not shown). DNA-PK, ATM, and ATR are also PI3K-related kinases susceptible to LY294002 inhibition, but these proteins are not likely to be involved in the apoptosis we observe, given their known mechanisms of action. The most relevant alternative to the PI3K-AKT pathway in our study are members of the Pim kinase family, also susceptible to LY294002 inhibition. However, we were unable to detect Pim kinase in any CTL lysates from our T-LGL patients (data not shown). Thus, taking into account the increased activity of the PI3K pathway that we have shown, and its well characterized AKT has many targets, including apoptosis signaling kinase-1 46 , MDM-2 47 , TSC2 48, 49 , GSK-3β 50 , BAD 51, 65 , AFX 52, 53 , and FKHR [54] [55] [56] [57] [58] . Thus, the PI3K pathway acting in part through AKT controls cell survival, proliferation, and metabolism on many levels and is an obvious point of interest for a disease involving dysregulated apoptosis, such as T-
LGL.
Our observation that a SFK is active and necessary for PI3K activity in T-LGL
suggests there is an upstream receptor that is activated and initiates this kinase activity.
Since cytokine receptors do not display intrinsic kinase activity, they rely on associated 59, 60 . A further interest in SFK relates to their ability to influence the activity of the PI3K pathway by inhibiting PTEN, the lipid phosphatase that dephosphorylates phosphatidylinositol 3-phosphate and attenuates PI3K signaling 61 . Thus, our finding of SFK-dependent PI3K activity strengthens the hypothesis that T-LGL is a disease of dysregulated homeostatic apoptosis.
Upon further analysis of PI3K-dependent signaling in T-LGL, we discovered that the mitogen activated protein kinase ERK is phosphorylated in the clonal CTL from T-
LGL patients. Therefore, we contend that PI3K-mediated activation of ERK in T-LGL is not directly related to the ability of the clonal CTL to avert apoptosis. The differential role of ERK activation in T-LGL versus NK-LGL may present an opportunity to further explore the pathophysiology of these related lymphoproliferative disorders and warrants further study.
In conclusion, we find that elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of "Achilles heel" for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTL after a short incubation. As novel inhibitors of PI3K and its downstream components become available for clinical applications, it will be interesting to further investigate their efficacy in T-LGL.
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